Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Dalfopristin/Quinupristin

CA-MRSA is susceptible to more antibiotics than HA-MRSA. Like HA-MRSA, CA-MRSA typically is sensitive to vancomycin, linezolid, daptomycin, tigecycline, and quinupristin/ dalfopristin, but it also may be sensitive to clindamycin, doxy-cycline, minocycline, and/or trimethoprim-sulfamethoxazole (TMP-SMX).14... [Pg.1078]

Regimen should include vancomycin, daptomycin, quinupristin/ dalfopristin or linezolid. ... [Pg.1085]

If the isolate is determined to be vancomycin-resistant, it is most important to know the exact species because some of the treatment options, such as quinupristin/dalfopristin, are not active against E. faecalis. Currently, the treatment options for vancomycin-resistant enterococci (VRE) are not well established by clinical studies or patient experience. The treatment recommendations for vancomycin-resistant E. faecium include linezolid or quinupristin/dalfopristin for a minimum of 8 weeks. However, newer agents, such as daptomycin, may provide another option for treatment for either enterococci species (E. faecium and E. faecalis). Additionally, guidelines suggest the use of imipenem-cilistatin plus ampicillin or ceftriaxone plus ampicillin for the treatment of E. faecalis with a minimum of 8 weeks of therapy. Consultation with an infectious diseases specialist is recommended. [Pg.1098]

Recommend consultation witir infectious disease specialist Linezolid, quinupristin/dalfopristin, daptomycin, tigecydine Staphylococcus aureu Staphylococcus epidermidis Methicillin (oxacillin) sensitive PRP ... [Pg.393]

Trimethoprim-sulfamethoxazole, doxycydine,e or clindamycin linezolid, quinupristin-dalfopristin, daptomycin, or tigecydine... [Pg.393]

For vancomyan-resistant fap/fy/ococ-cus aureus, linezolid, daptomydn, or quinupristin-dalfopristin must be used... [Pg.474]

Linezolid or quinupristin-dalfopristin should be used to treat vancomycin-resistant enterococcus not susceptible to ampicillin... [Pg.474]

Initial therapy with trimethoprim-sulfamethoxazole appears to be effective for CA-MRSA and should be considered in geographic areas in which CA-MRSA are commonly encountered. Alternative agents for documented infections with resistant gram-positive bacteria such as methicil-lin-resistant staphylococci and vancomycin-resistant enterococci include linezolid, quinupristin/dalfopristin, daptomycin, and tigecycline. [Pg.530]

Kehoe, L. E., Snidwongse, J., Courvalin, P., Rafferty, J. B., and Murray, I. A. (2003). Structural basis of Synercid (quinupristin-dalfopristin) resistance in Gram-positive bacterial pathogens. / Biol. Chem. 278, 29963-29970. [Pg.93]

TABLE 4.6 Quinupristin-Dalfopristin Susceptibility and Genetic Determinants of Resistance in Enterococcus faecium from Different Midwestern U.S. Ecologic Sources... [Pg.202]

E. faecium Source %Susceptibility to Quinupristin-Dalfopristin %Resistance Genes ... [Pg.202]

Hayes J.R., A.C. McIntosh, S. Qai3mmi, J.A. Johnson, L.L. Enghsh, L.E. Carr, D.W. Wagner, and S.W. Joseph (2001). High-frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from poultry production environment. Journal of Clinical Microbiology 39 2298-2299. [Pg.265]

Werner G., I. Klare, and W. Witte (1998). Association between quinupristin/dalfopristin resistance in gylcopeptide-resistant Enterococcus faecium and the use of additives in animal feed. European Journal of Clinical Microbiology and Infectious Diseases 17 401-402. [Pg.290]

Quinupristin-dalfopristin is approved for treatment of infections caused by staphylococci or by vancomycin-resistant strains of E faecium, but not E faecalis, which is intrinsically resistant probably because of an efflux-type resistance mechanism. The principal toxicities are infusion-related events, such as pain at the infusion site, and an arthralgia-myalgia syndrome. [Pg.1013]

Quinupristin-dalfopristin is administered intravenously at a dosage of 7.5 mg/kg every 8-12 hours. Peak serum concentrations following an infusion of 7.5 mg/kg over 60 minutes are 3 g/mL for quinupristin and 7 ufmL for dalfopristin. Quinupristin and dalfopristin are rapidly metabolized, with half-lives of 0.85 and 0.7 hours, respectively. Elimination of approximately 75% of the parent compounds and their metabolites is by the fecal route. Renal elimination accounts for less than 20%. Dose adjustment is not necessary for renal failure, peritoneal dialysis, or hemodialysis. [Pg.1067]

Quinupristin-dalfopristin is approved for treatment of infections caused by vancomycin-resistant... [Pg.1067]

Trimethoprim-sullamelfioxazol doxycycline, or clindamydnf linezolirt quinupristin-dalfopristin, dapto-mydn, or tigecycline... [Pg.380]

See other pages where Dalfopristin/Quinupristin is mentioned: [Pg.1098]    [Pg.404]    [Pg.405]    [Pg.358]    [Pg.198]    [Pg.179]    [Pg.491]    [Pg.270]    [Pg.51]    [Pg.200]    [Pg.201]    [Pg.201]    [Pg.201]    [Pg.202]    [Pg.1071]    [Pg.615]    [Pg.1013]    [Pg.1013]    [Pg.11]    [Pg.1067]    [Pg.1068]    [Pg.1178]    [Pg.391]    [Pg.392]    [Pg.9]   
See also in sourсe #XX -- [ Pg.270 ]

See also in sourсe #XX -- [ Pg.270 ]

See also in sourсe #XX -- [ Pg.230 ]

See also in sourсe #XX -- [ Pg.389 , Pg.389 ]

See also in sourсe #XX -- [ Pg.270 ]



SEARCH



Dalfopristin

Quinupristin

© 2024 chempedia.info